Kerala Ayurveda Limited has announced the grant of stock options to its employees under the Employee Restricted Stock Unit Plan 2023. The company's Nomination Remuneration Committee approved this significant employee benefit initiative on December 10, 2025.

Stock Option Grant Details

The committee approved the grant of 1,54,752 options at an exercise price of ₹10 per option to eligible employees. This grant represents a substantial allocation under the ESOP 2023 scheme, designed to align employee interests with long-term company performance.

Vesting Schedule and Structure

The options will vest over a 4-year period with specific vesting schedules for different employee categories. For the majority of employees, the vesting follows equal annual installments:

Standard Vesting Schedule:

• 25% at the end of first year from grant date
• 25% at the end of second year (cumulative 50%)
• 25% at the end of third year (cumulative 75%)
• 25% at the end of fourth year (cumulative 100%)

Alternative Vesting for Four Employees:

• 33.33% at the end of first year from grant date
• 33.33% at the end of second year (cumulative 66.66%)
• 33.34% at the end of third year (cumulative 100%)

Exercise and Share Conversion

Once vested, option holders will have one year within which the options may be exercised. Upon exercise, the 1,54,752 options will convert into an equal number of equity shares with a face value of ₹10 each, assuming all granted options are vested and exercised.

Scheme Administration

The ESOP 2023 is administered by the Nomination and Remuneration Committee of the company. The grant of options is based upon eligibility criteria as mentioned in the scheme. The granted options, once vested, will entitle option holders to acquire an equal number of equity shares upon payment of exercise price and applicable taxes in accordance with the terms and conditions of the scheme.

This employee stock option grant reflects Kerala Ayurveda's strategy to retain talent and provide employees with opportunities to participate in the company's growth through equity participation.

Kerala Ayurveda Limited (KAL), a leading Ayurvedic healthcare company, has reported a 27% revenue growth in the first half of the fiscal year, with revenues reaching Rs. 74.62 crores. The company has also announced its Vision 2030 plan, targeting an expansion to Rs. 1000 crores by 2030.

Financial Performance

KAL's financial results for the half-year ended September 30 showcase performance across various business segments:

The company maintained a positive adjusted EBITDA of Rs. 4.40 crores, despite continued investments in talent, marketing, and infrastructure.

Segment-wise Performance

Kerala Ayurveda reported growth across its key business segments:

Additionally, the company has expanded its global footprint with the addition of a new clinic business in Singapore.

Vision 2030: Scaling New Heights

Kerala Ayurveda has unveiled its Vision 2030 plan, setting targets for the coming years:

1. Overall Target: Aim for revenues of Rs. 1000 crores by 2030
2. Global E-Product Business: Target 20x growth
3. Health Services Business: Aim for 10x growth

Management Commentary

Dr. K. Anilkumar, Executive Director of Kerala Ayurveda Limited, stated in the company's financial report, "The company has demonstrated strong performance across key business segments, particularly in India E-commerce and US Wellness centres. Our Vision 2030 plan sets ambitious targets that reflect our confidence in the growing demand for Ayurvedic products and services globally."

Future Outlook

Kerala Ayurveda's performance in H1 and its Vision 2030 plan indicate the company's commitment to growth and expansion in the Ayurvedic healthcare sector. The focus on scaling up its global E-Product business and Health Services business suggests an approach to capturing larger market share both domestically and internationally.

As the company continues to invest in talent, marketing, and infrastructure, it aims to capitalize on the interest in Ayurvedic and natural healthcare solutions. The addition of the Singapore clinic business also signals Kerala Ayurveda's intent to expand its international presence.

Investors and industry observers may be watching Kerala Ayurveda's progress as it works towards its Vision 2030 goals, particularly in light of the evolving global healthcare landscape and consumer interest in alternative and traditional medicine.